8-K: HUMBL Restructures Multicortex Joint Venture, Gains Flexibility and Retains Capital

HUMBL, Inc. terminated its Joint Venture Agreement with Multicortex, LLC, opting instead for a one-year option to acquire a controlling interest and eliminating a revenue share obligation.

Summary

• HUMBL, Inc. and Multicortex, LLC terminated their Joint Venture Agreement, originally established on April 3, 2025.
• The previous JV Agreement would have made Multicortex a 51% subsidiary of HUMBL upon payment of a $3,000,000 purchase price, and HUMBL would pay 15% of any Regulation A+ offering proceeds to Multicortex, up to $3,000,000.
• Under the new Termination Agreement, HUMBL received a one-year option to purchase 51% of Multicortex for $3,000,000.
• HUMBL's obligation to pay 15% of Regulation A+ proceeds to Multicortex was terminated.
• Common shares of HUMBL issued to Multicortex founders, Bruno Ghizoni and Alessandro Faria, will be cancelled.
• HUMBL will continue to provide introductions and sales support for Multicortex, with parties agreeing to negotiate sales commissions in good faith.

Sentiment

Score: 8

Explanation: The filing presents the termination and new option as a 'superior' outcome for HUMBL, emphasizing increased flexibility, retained capital, and more time for evaluation, along with the cancellation of previously issued shares. This indicates a strong positive sentiment from the company's perspective.

Positives

• HUMBL gained an option to purchase a controlling interest in Multicortex, providing flexibility without immediate commitment.
• HUMBL now has full control of any proceeds from a future Regulation A+ offering, as the 15% payment obligation to Multicortex was terminated.
• The company has more time (one year) to evaluate Multicortex's business prospects before deciding on an acquisition.
• Common shares of HUMBL previously issued to Multicortex founders will be cancelled, which is beneficial for existing shareholders by reducing potential dilution.

Negatives

• The termination of the definitive Joint Venture Agreement and its replacement with an option could indicate a delay or uncertainty in the original acquisition strategy.
• The initial commitment to acquire Multicortex as a 51% subsidiary was replaced by a less binding option, potentially signaling a re-evaluation of Multicortex's immediate value or HUMBL's financial capacity.

Risks

• There is no guarantee that HUMBL will exercise its option to purchase 51% of Multicortex within the one-year period.
• The agreement to negotiate sales commissions in good faith for HUMBL's sales support introduces potential for future disagreements or unfavorable terms if negotiations are not successful.
• The underlying reasons for terminating the original JV Agreement, if related to Multicortex's performance or HUMBL's financial position, could pose ongoing risks.

Future Outlook

HUMBL now has a one-year option to acquire a controlling 51% interest in Multicortex, providing flexibility to evaluate Multicortex's business prospects further. The company retains full control over any future Regulation A+ offering proceeds, which were previously subject to a 15% payment obligation. HUMBL will continue to support Multicortex with sales and introductions, with future sales commissions to be negotiated.

Management Comments

• HUMBL believes that the Termination Agreement is a superior option to the Joint Venture Agreement because it still provides HUMBL the ability to purchase a controlling interest in Multicortex, but with the added flexibility of full control of any proceeds from a Regulation A+ offering and more time to evaluate Multicortex's business prospects.

Industry Context

NA

Related Party Transactions

• The termination of the Joint Venture Agreement and the granting of a purchase option involve Multicortex, a party with whom HUMBL had a prior significant business relationship.
• The cancellation of HUMBL common shares issued to Bruno Ghizoni and Alessandro Faria, founders of Multicortex, constitutes a related party transaction.
• Ongoing agreement for HUMBL to provide introductions and sales support to Multicortex, with future sales commissions to be negotiated, represents continued related party dealings.

Stakeholder Impact

• Shareholders: Benefit from the cancellation of previously issued shares, reducing potential dilution. Also benefit from HUMBL retaining full control of future Regulation A+ offering proceeds, potentially increasing capital available to the company.
• Multicortex: Gains continued sales support and introductions from HUMBL, but loses the immediate prospect of becoming a 51% subsidiary and the guaranteed 15% share of HUMBL's Regulation A+ proceeds.
• Multicortex Founders (Bruno Ghizoni, Alessandro Faria): Their HUMBL common shares will be cancelled.

Next Steps

• HUMBL has a one-year period to exercise its option to purchase a 51% equity interest in Multicortex for $3,000,000.
• HUMBL will continue to provide introductions and sales support for Multicortex.
• HUMBL and Multicortex will work in good faith to negotiate appropriate sales commissions for HUMBL's efforts.
• Multicortex will cause its founders, Bruno Ghizoni and Alessandro Faria, to execute documents necessary to cancel HUMBL common shares issued to them.

Key Dates

Recommendation

The termination of the original JV and the shift to an option, while framed positively by management due to increased flexibility and retained capital, introduces uncertainty regarding the long-term strategic direction with Multicortex. The cancellation of shares is a clear positive for existing shareholders, but the overall impact on future growth and profitability remains to be seen. Given the restructuring, a 'hold' recommendation is appropriate to observe how HUMBL leverages its newfound flexibility and whether the option is ultimately exercised, and how the sales commission negotiations proceed.

Keywords

HUMBL, Multicortex, Joint Venture, Termination Agreement, Option to Purchase, Regulation A+ Offering, Share Cancellation, SEC Filing, 8-K, Corporate Restructuring, Equity Interest